2022---eli-lilly-and-company--goldman-sachs-maintains-its-neutral-opinion ✪

Concerns that the stock had become a "crowded trade," making it vulnerable to any minor earnings misses or clinical setbacks. Market Impact

In a year marked by significant shifts in the pharmaceutical landscape, reaffirmed its Neutral rating on Eli Lilly and Company (LLY) during 2022. While the drugmaker demonstrated robust growth potential driven by its late-stage pipeline, analysts at the investment bank remained cautious regarding the stock’s valuation and broader macroeconomic headwinds. The 2022 Backdrop: Growth vs. Valuation

AI responses may include mistakes. For financial advice, consult a professional. Learn more Concerns that the stock had become a "crowded

The FDA approval of tirzepatide for type 2 diabetes in May 2022 served as a major catalyst for the stock.

Throughout 2022, Eli Lilly emerged as a standout performer in the healthcare sector, largely due to excitement surrounding its blockbuster potential in diabetes and obesity treatments. Specifically, the launch and clinical success of positioned the company as a leader in a rapidly expanding market. The 2022 Backdrop: Growth vs

A recognition of Lilly’s best-in-class R&D and commercial execution.

The maintenance of the Neutral stance did little to dampen investor enthusiasm in the long term. While the rating suggested a lack of immediate "buy" urgency from the bank's perspective, Eli Lilly finished 2022 as one of the best-performing large-cap pharmaceutical companies, setting the stage for its continued ascent in the years that followed. Learn more The FDA approval of tirzepatide for

Investors closely watched the progress of donanemab , Lilly’s experimental Alzheimer’s drug, which faced a complex regulatory environment following the controversial rollout of rival treatments.